-
1
Danegaptide is an oral drug for non-proliferative diabetic retinopathy.
-
2
The phase 1b trial involved 24 patients across 11 sites.
-
3
It aims to stabilize gap-junctions and counter VEGF effects.
-
4
The trial met objectives of safety, tolerability, and showed early signs of effectiveness.
-
5
Orally administered treatments may improve patient adherence.
-
6
It addresses significant unmet needs in earlier stages of diabetic retinopathy.
-
7
Potential to reduce treatment burden from repeated injections.
Original Source(s)
Related Content
GLP-1 Eye Effects Raise Questions
Authors describe both potential retinal benefits and possible rare optic nerve risks, while emphasizing that long-term ocular safety data remain limited as use expands.
by Kerri Miller
March 24, 2026
-
2 min
EYP-1901 in Wet AMD and DME: Insights from the Phase 2 DAVIO 2 and VERONA Trials
An overview of key visual and anatomic findings with EYP-1901 from the DAVIO 2 and VERONA clinical trials, presented at Macula Society 2026
March 24, 2026
-
6 min
Why Glaucoma Prevalence Is Rising
... and what the eye care community must do next
March 24, 2026
-
4 min
